MSCI India Index Aug 2026: $3.2bn inflows outlook

JM Financial flags likely MSCI upgrade candidates

JM Financial Institutional Securities has identified Laurus Labs Ltd and Biocon Ltd as high-probability candidates for inclusion in the MSCI India Standard Index from the MSCI Small Cap Index in the August review cycle. The brokerage said both stocks qualify for potential large-cap upgrades after improvements in market capitalisation and liquidity metrics. In the same note, JM Financial estimated that the broader rejig could lead to sizeable passive flows into Indian equities. For investors tracking index-driven demand, the MSCI review is watched closely because changes can create one-time inflows and outflows from passive funds. The focus in this cycle is not only on potential additions and deletions but also on “migrations” from the small-cap index to the standard index.

Key dates for the August 2026 MSCI review

JM Financial said the MSCI India Standard Index rebalancing announcement is scheduled for August 12, post-market hours. The changes, once announced, are expected to take effect on August 31. Such timelines matter because passive funds typically rebalance around the effective date, concentrating flows into a narrow window. The brokerage’s estimates are presented as indicative figures rather than certainties. It also noted that its flow calculations assume no concurrent changes in country-level weights or an emerging markets index rebalancing.

Estimated passive flows: inflows, outflows, and net impact

According to the report, the rejig could see as many as 12 inclusions and one exclusion, with an estimated inflow of $1.2 billion. JM Financial further broke this down at an aggregate level, estimating passive inflows into India of about $1.4 billion and outflows of approximately $159 million. That results in a net positive passive inflow of roughly $1.2 billion. These numbers frame the magnitude of potential demand, but they remain sensitive to the final MSCI list and to any broader index-level adjustments.

Inclusion candidates: Ather Energy and SAIL in focus

Beyond the upgrade discussion, JM Financial also highlighted candidates for direct inclusion in the MSCI India Standard Index. It said Ather Energy and Steel Authority of India Ltd (SAIL) are leading candidates for inclusion, flagged as medium-probability additions. The brokerage noted they are “close to adequate free-float adjusted market cap above MSCI's minimum size threshold.” This suggests that marginal changes in free-float market cap could influence their final eligibility.

Migration candidates: Laurus Labs and Biocon seen as high probability

Among migration candidates, JM Financial’s clearest calls were on Laurus Labs and Biocon as “high-probability candidates” to move from the MSCI Small Cap Index to the MSCI India Standard Index in this review cycle. The brokerage attributed this to the recent improvement in their market capitalisation and liquidity metrics. It also positioned these moves as potential large-cap upgrades, a category that can attract substantial passive allocations. In the same list, JM Financial also mentioned Apar Industries, Uno Minda, Glenmark, Coforge, and Thermax with lower probability levels, indicating a wider funnel of possible changes.

Stock-specific flow estimates for migration candidates

JM Financial provided estimated passive inflow figures for several migration candidates. Laurus Labs may attract $196 million of inflows, followed by Biocon with $195 million. Apar Industries was listed with $161 million (medium probability) and Uno Minda with $105 million (medium probability). Among low-probability names, Glenmark was pegged at $110 million, Coforge at $114 million, and Thermax at $100 million. These figures illustrate how index transitions can matter even without any change in a company’s underlying earnings trajectory.

Why Laurus Labs stands out beyond the index event

JM Financial’s index note coincides with a broader narrative around Laurus Labs’ business mix. The company has indicated a push from small-molecule chemistry toward more complex areas, including peptides and antibody drug conjugates (ADCs), alongside flow chemistry and other advanced capabilities. It also signalled a focus on long-term global partnerships supported by continuous capex plans. In its commentary, Laurus has stated it wants to keep its position in ARVs (small molecules) while building capabilities in peptides and ADCs (large molecules). The company’s CDMO side business has grown at 50% for the last nine months, with what it described as strong recurring business, and it expects the human CDMO segment to remain a primary growth driver.

Laurus operating metrics and investment signals cited in notes

Operational metrics referenced in the provided material include generics business revenues growing 37% in Q3, and overall Q3 growth of 26%, with nine-month revenue up 30% and “crossing ₹5,000 crore for first time in 9 months.” It also cites ROCE at 18.5% and mentions planned capex of ₹1,000 crore this year with a similar capex expectation next year, linked to expansion plans. Separately, Laurus Labs generated ₹5,554 crore in revenue in FY2025, and the company reported it employs over 7,042 people, including 2,632+ scientists, operating 15 facilities approved by regulators such as the USFDA, WHO and EMA.

Biocon: MSCI upgrade watch and segment growth outlook

Biocon is also on JM Financial’s high-probability upgrade list for the MSCI India Standard Index. Separately, a Motilal Oswal update referenced in the material reiterates a Buy on Biocon, citing biosimilars leadership, and projects Biocon’s biologics segment to grow 22% year-on-year. While the MSCI decision is rules-based, such operating trends can influence market capitalisation and liquidity over time, which are inputs in eligibility screens. For index-focused investors, the key near-term variable is whether Biocon’s metrics remain above the required thresholds through the cut-off.

Market impact: what passive flows can and cannot tell you

If MSCI changes lead to the projected net passive inflow of roughly $1.2 billion, the immediate effect is typically felt through demand for names that are added or upgraded and selling pressure on those removed. However, JM Financial explicitly described the estimates as indicative and dependent on assumptions such as no country-weight changes. The report’s own numbers also show that while inflows can be large, outflows are not zero, with about $159 million of estimated outflows at the aggregate level. The most actionable implication for investors is the calendar, with August 12 as the announcement date and August 31 as the effective date, around which liquidity can be concentrated.

Why this MSCI review matters for Indian equities

The August 2026 MSCI review matters because it combines a potentially high number of changes with meaningful estimated flows. JM Financial’s mention of up to 12 inclusions and one exclusion signals a broader reshaping than a routine, minimal-change cycle. For companies like Laurus Labs and Biocon, an upgrade from small-cap to standard can expand their passive ownership base, as more global funds track standard indices. For the market, the aggregate figure of about $1.2 billion in net positive passive inflow provides a measurable reference point for index-related demand, even as the final outcome depends on MSCI’s rules and cut-offs.

Conclusion: what to watch next

JM Financial’s note sets a clear near-term checklist: the MSCI India Standard Index announcement on August 12 and the implementation on August 31. Laurus Labs and Biocon are flagged as high-probability migration candidates, with estimated inflows of $196 million and $195 million respectively, if included. Ather Energy and SAIL are highlighted as medium-probability inclusion candidates, described as close to meeting the free-float market-cap threshold. The next definitive update will come with MSCI’s post-market announcement, after which passive rebalancing activity typically shifts from expectation to execution.